Browse by category

Researchers at Lund University and AstraZeneca have reported that integrating measurements such as body fat percentage and waist circumference captures disease risks missed by BMI alone. This study provides increasing evidence for including more parameters than BMI in the diagnosis of obesity. In recent years, research has shown that there are several limitations with BMI alone when it comes to assessing adiposity quantity, distribution, as well as the risk of developing vari

Endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity, according to the outcomes from a comparative study, ‘Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real World Comparative Study’, presented at the European Society of Gastrointestinal Endoscopy (ESGE) Days 2026. Endoscopic sleeve gastroplasty is a minimally invasive endoscopic procedure that reduces gastric

Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg. Bariatric surgery is an effective treatment for obesity and type 2 diabetes, but patient outcomes vary widely. The current study, published in Nature Metabolism, suggests that the variations are partly explained by differences in how the composition of gut bacter

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to research ‘‘Examining trends in the decline of bariatric surgery – an MBSAQIP analysis (Abstract ID: 4730)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. Tyler Cohn “After years of steady growth, the number of metabolic and b

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 - according to a new real-world analysis ‘Trends of bariatric surgery utilization in patients with severe obesity in the era of GLP-1 use for weight loss (Abstract ID: 4393)’ - presented at the annual scient

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to research, ‘Bariatric surgery effectiveness after glp-1 agonist weight loss (abstract id: 4149)’, presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. “Patients are increasingly having surgery after GLP-1 therapy,

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to research, ‘Understanding insurance-based differential healthcare costs for GLP-1ra versus bariatric surgery (abstract id: 4339)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. “As GLP-1 use bec

Metabolic and bariatric surgery offers significantly greater long-term protection against major adverse cardiovascular events (MACE, eg heart attack, stroke) and death than GLP-1 drugs in older adults with obesity and diabetes, according to real-world analysis study, ‘Cardiometabolic outcomes of metabolic surgery versus GLP-1 receptor agonists in older adults with diabetes and obesity (Abstract ID: 4719)’, presented at the annual meeting of the American Society for Metabolic

Most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment, accord to research presented at the European Congress on Obesity in Istanbul, Turkey. The study is by Dr Louis J Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, New York, NY, and colleagues. While the efficacy of injectable therapies has been repeatedly proven in clinical trials, how

A systematic review and meta-analysis of studies, ‘Effects of Incretin-Based Therapies, Diet and Exercise interventions, and Bariatric Surgery on Fat-Free Mass in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis’, presented at the European Congress on Obesity in Istanbul, Turkey, shows that diet and exercise interventions result in a lower proportion of fat-free mass loss compared with bariatric surgery or obesity drugs among people undergoing a weight